Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05095467
Other study ID # B2021-574
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date October 2021
Est. completion date October 2026

Study information

Verified date October 2021
Source Shanghai Zhongshan Hospital
Contact Xuefei Wang, MD
Phone +86 13917270428
Email wang.xuefei@zs-hospital.sh.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

HIPEC-AS01 is an open, prospective, single-center phase II clinical study, which will include "cT4aNxM0, P0 or cTxNxM1, P1" patients with gastric or esophagogastric junction adenocarcinoma, to evaluate the efficacy and safety of systemic chemotherapy with HIPEC combined with AS in the perioperative period. Patients enrolled will be divided into three groups. Among them, group A is the patients with locally resectable GC; group B is patients with peritoneal metastasis stage P1a or P1b, group C is patients with peritoneal metastasis stage P1c. The primary purpose is to evaluate the 3-year overall survival rate.


Description:

HIPEC-AS01 is an open, prospective, single-center phase II clinical study, which will include Patients With cT4aNxM0, P0, or cTxNxM1*, P1 Adenocarcinoma of the Stomach or Esophagogastric Junction, to evaluate the efficacy and safety of systemic chemotherapy with HIPEC combined with AS in the perioperative period. Patients enrolled will be divided into three groups. Among them, group A is the patients with locally resectable GC; group B is patients with peritoneal metastasis stage P1a or P1b, group C is patients with peritoneal metastasis stage P1c. Intervention: Group A: 1 cycle HIPEC+S-1 chemotherapy, sequential 3 cycles of chemotherapy (AS plan, Q21d × 3), surgery+HIPEC, sequential 3 cycles of chemotherapy ( AS plan, Q21d × 3). Group B: 1 cycle HIPEC+S-1 chemotherapy, sequential 3 cycles of chemotherapy (AS plan, Q21d × 3), surgery+HIPEC, sequential 3 cycles of chemotherapy ( AS plan, Q21d × 3). Group C: 1 cycle HIPEC+S-1 chemotherapy, sequential 3 cycles of chemotherapy (AS plan, Q21d × 3), HIPEC+S-1 chemotherapy, sequential 3 cycles of chemotherapy ( AS plan, Q21d × 3). In this study, the patient's overall survival was the main evaluation index. It is estimated that the case recruitment will be completed in 2 years, and the follow-up time will be 3 years. The total sample size is approximately 157 cases.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 157
Est. completion date October 2026
Est. primary completion date October 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. 18 years old = age = 75 years old; 2. The primary gastric lesion was diagnosed as gastric or esophagogastric junction adenocarcinoma (papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma, and poorly differentiated adenocarcinoma. ) 3. The tumor is located in the stomach or esophagogastric junction (Siewert type II/III) 4. The preoperative clinical staging is cT4aNxM0, P0 or cTxNxM1*, P1 (*no other distant metastases except peritoneal metastasis) 5. Good bone marrow reserve function: HB=90g/L; ANC =1.5×10*9/L; PLT =80×10*9/L 6. Good liver and kidney function reserve: BIL = 1.5 times the upper limit of normal (ULN); ALT and AST = 2.5×ULN; Crea=1×ULN; 7. Good coagulation function: International normalized ratio (INR) or prothrombin time (PT) = 1.5 times ULN, activated partial thromboplastin time (APTT) = 1.5 times ULN 8. ECOG (Eastern Cooperative Oncology Group) physical status score 0-2; 9. No prior treatment of chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc; 10. Written informed consent. Exclusion Criteria: 1. There are distant metastases other than peritoneal metastases; 2. Complications of gastric cancer require emergency treatment, such as bleeding, perforation, obstruction, etc.; 3. Suffer from other malignant tumors within five years; 4. Body temperature =38? or complicated with infectious diseases requiring systemic treatment; 5. If there is a history of uncontrolled epilepsy, central nervous system disease, or mental disorder, the investigator will determine whether the clinical severity hinders the signing of informed consent or affects the patient's compliance with oral medications; 6. Clinically serious (ie active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) grade II or more severe congestive heart failure, or severe arrhythmia requiring drug intervention, or recent history of myocardial infarction within 12 months; 7. Severe respiratory diseases; 8. Severe liver and kidney dysfunction; 9. Upper gastrointestinal obstruction or abnormal physiological function or malabsorption syndrome, which may affect the absorption of oral drugs; 10. Diseases such as severe diabetes, hyperthyroidism and hypothyroidism have not been clinically controlled. 11. Those who continue to use glucocorticoid therapy within 1 month (except for local application) or who require immunosuppressive therapy for organ transplantation; 12. Pregnant or lactating women; 13. The patient has participated or is participating in other clinical studies (within 6 months);

Study Design


Intervention

Procedure:
HIPEC
The abdominal cavity will be filled with paclitaxel 120mg/m2 heated at 43? for 1 hour with a hyperthermic circulation machine.
Drug:
Paclitaxel-albumin
albumin paclitaxel D1, D8; S-1: D1-D14
Tegafur-gimeracil-oteracil potassium
40mg bid(BSA<1.5 m2) ,60mg bid(BSA>=1.5 m2); D1-D14, po, bid.
Procedure:
Surgery+HIPEC
gastrectomy with D2 lymphadenectomy+HIPEC procedure

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Xuefei.Wang

Outcome

Type Measure Description Time frame Safety issue
Primary 3-year Overall Survival, OS The time from the date of enrollment of the patient to the date of death or the date of the last follow-up 3 years
Secondary 3-year Progression Free Survival, PFS The time from the date of enrollment of the patient to the first occurrence of disease progression or death from any cause. 3 years
Secondary NCI CTC Adverse Events Version 4.0 Safety of HIPEC-AS plan 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT01950572 - Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Recruiting NCT05161572 - Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer Phase 2
Not yet recruiting NCT04351867 - A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric Cancer Phase 3
Recruiting NCT02887612 - ctDNA for Prediction of Relapse in Gastric Cancer
Active, not recruiting NCT02930291 - The Effect of Preoperative Inflammation-based Scores on Postoperative Morbidity and Mortality for Laparoscopic Gastrectomy
Completed NCT02649348 - Effects of Prehabilitation in Gastric Cancer Patients With Metabolic Syndrome on Perioperative Outcome N/A
Recruiting NCT02310230 - An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy N/A
Active, not recruiting NCT01609309 - Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01) Phase 3
Completed NCT00382720 - Docetaxel and Oxaliplatin in Gastric Cancer Phase 2
Completed NCT00375999 - Docetaxel and Epirubicin in Advanced Gastric Cancer Phase 2
Completed NCT00980382 - A Phase I/II Study of S-1 and Weekly Docetaxel for Metastatic Gastric Carcinoma Phase 1/Phase 2
Recruiting NCT05007106 - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Phase 2
Active, not recruiting NCT05602935 - Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study Phase 2
Recruiting NCT05033392 - PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer Phase 2
Completed NCT04539769 - Impact of the Type of Reconstruction Methods on Diabetes Following Laparoscopic Distal Gastrectomy in Patients With Gastric Cancer and Type 2 Diabetes Phase 2
Active, not recruiting NCT02845986 - Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer Phase 2
Active, not recruiting NCT02930278 - The Effect of Preoperative Hemotologic Markers on Postoperative Long-term and Short-term Outcomes for Laparoscopic Gastrectomy
Completed NCT02902575 - The Safety and Feasibility of Laparoscopic-assisted Gastrectomy for Advanced Gastric Cancer After Neoadjuvant Chemotherapy N/A
Recruiting NCT04222114 - Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis Phase 3
Recruiting NCT05068180 - Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients Phase 4